Participated in Unravel Health's £2.5M pre-seed co-led by Conduit EIS Impact Fund and Wrightwood.
OCT 16, 2026
Develops a patented saliva-based biosensor that measures multiple hormones and related biomarkers in near real time, enabling non-invasive, longitudinal tracking of women's hormonal health and symptom patterns
Develops a patented saliva-based biosensor that measures multiple hormones and related biomarkers in near real time, enabling non-invasive, longitudinal tracking of women's hormonal health and symptom patterns. The company also aims to build a dense data layer for research, clinical trials, and personalized care.